Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lunsekimig in moderate-to-severe atopic dermatitis
NCT06790121Phase 2Completed
- Sponsor
- Sanofi
- Start
- Jan 2025
- Primary completion
- Feb 2026
- Modality
- Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of lunsekimig in atopic dermatitis (AD) (6 arms), sponsored by Sanofi. Primary endpoint: Percent change in Eczema Area and Severity Index at 24 weeks. Started Jan 2025; status: completed.
02
Drugs
lunsekimig
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06790121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06790121.